At Novo Nordisk, there are numerous adjustments to the areas of responsibility as a result of a withdrawal from the management level.
• Camilla Sylvest resigns from Novo Nordisk after 28 years
• Resignation requires an extensive reorganization of responsibilities
• Already the second significant change of management at Novo Nordisk in a short time
After 28 years in the company on Thursday, Camilla Sylvest, who had been working as an executive Vice President for Commercial & Corporate Affairs at the Pharmariehen Novo Nordisk for seven years, announced her recovery.
Extensive adjustments in the management necessary
Sylvest, who worked in her position as head of commercial strategy and corporate matters, had originally started as a trainee at Novo Nordisk and worked up to the management. Why she now wants to end her career with the Danish pharmaceutical manufacturer does not show from the press release published by Novo Nordisk.
However, their decline now makes numerous adjustments to the management level necessary. Ludovic Helfgott, Executive Vice President for Rare Diseases, is to take on responsibility for product and portfolio strategy, including the commercial strategy, medical affairs and business development in all therapy areas.
Thilde Hummel Bøgebjerg, Senior Vice President for Product Supply and new technologies, is also promoted to the Executive Vice President for Quality, IT and Environment, while Tania Sabroe, Executive Vice President for Personnel and Organization, should also take responsibility for global communication.
Second change to the management level in a short time
The resignation of Camilla Sylvest has recently been the second important leadership change at Novo Nordisk. Previously, Bloomberg had reported on the change of Morten Lammert, Corporate Vice President for obesity and global strategy development in a newly created position at Roche, but it has not yet been officially confirmed by the company page.
The Novo Nordisk share will declare 2.42 percent to 445.80 DKK on Friday on Friday.
Editor finance.net
Selected leverage products on Novo Nordisk
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Novo Nordisk
The lever must be between 2 and 20
Advertising